A record of what Macquarie Analysis said publicly, with the source. Not advice.
“Bullish on Max Healthcare; upgraded to Outperform and raised price target to ₹1,450 from ₹825, implying a 37% upside. The brokerage cites disciplined capital allocation, stronger EBITDA growth outlook, and a favourable capacity expansion trajectory, with expected CAGR of 20% revenue and 22% EBITDA over FY26–FY29.”
Macquarie Analysis’s track record (trackable calls only): 58 graded calls · 95% CI 49–73%
How this call is judged
A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.
No entry price is stated, so the call starts at the first close after it was published.
Target ₹1,450, as stated.
Window: 12 months, the default when no time frame is stated.
Window still open: no verdict until a close reaches a level or the window ends.
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.